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2040ABSTRACT
Background. Two large, prospective studies (12-03; OSAKA) compared the efficacy and
tolerability of prolonged-release versus immediate-release tacrolimus in kidney transplant
patients also receiving mycophenolate mofetil and low-dose corticosteroids (without
induction therapy).
Methods. Data were combined into one database to compare results over 24 weeks using
3 alternative endpoints: biopsy-confirmed acute rejection (BCAR); the Food and Drug
Administration composite endpoint (graft loss, BCAR, and loss to follow-up), and the
European Medicines Agency composite endpoint (graft loss, BCAR, and graft
dysfunction). The 95% confidence intervals were calculated (10% noninferiority margin).
Results. Overall, 633 patients received prolonged-release tacrolimus (12-03, n ¼ 331;
OSAKA, n ¼ 302) and 645 received immediate-release tacrolimus (n ¼ 336; n ¼ 309).
Baseline characteristics were comparable. Proportionately more patients receiving
prolonged-release tacrolimus had trough levels of 5e15 ng/mL on day 1 (60.8%) and 2
(56.6%) versus immediate-release tacrolimus (42.5% and 43.9%, respectively, both
P < .001). Efficacy of prolonged-release and immediate-release tacrolimus were similar
as assessed by BCAR (13.9% vs 14.1%, respectively), European Medicines Agency
composite endpoint (40.3% vs 38.3%) and US Food and Drug Administration
composite endpoint (21.5% vs 19.8%).K. Krämer, Laetitia Albano, and Bernhard Banas
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PROLONGED- AND IMMEDIATE-RELEASE TACROLIMUS 2041Conclusions. Novel efficacy endpoints as required by the European Medicines Agency
and US Food and Drug Administration demonstrate noninferiority of prolonged-release
versus immediate-release tacrolimus. Significantly more patients treated with prolonged-
release tacrolimus versus immediate-release tacrolimus achieved trough levels of 5 to 15
ng/mL early after transplantation. ClinicalTrials.gov NCT00189839; NCT00717470.DESPITE improvements in short-term graft survivalafter kidney transplantation, long-term graft and
patient outcomes have not shown similar improvements
[1,2]. Improving long-term outcomes therefore remains a
major challenge facing clinicians today [3].
Ensuring appropriate exposure to immunosuppressive
therapy posttransplantation plays a crucial role in
improving long-term outcomes, particularly in the imme-
diate posttransplant period, as increased intrapatient vari-
ability in exposure is associated with poorer outcomes
[4e10]. The once-daily, prolonged-release formulation of
tacrolimus was developed to provide more consistent
exposure, reduce intrapatient variability, and improve
adherence [11e13]. Data for this formulation have
demonstrated comparable steady-state exposure to the
twice-daily, immediate-release formulation in de novo kid-
ney transplant recipients [14,15], and showed significantly
lower intrapatient variability in tacrolimus trough concen-
trations in stable kidney transplant recipients converted
from immediate-release tacrolimus [11,12,16]. However,
variability in exposure for prolonged-release versus
immediate-release tacrolimus has not previously been
compared in de novo kidney transplant recipients. Although
achieving potential long-term benefits is the ultimate goal
for prolonged-release tacrolimus, it is first necessary to
demonstrate that the short-term efficacy of the prolonged-
release formulation is comparable with that of the
immediate-release tacrolimus formulation.
Two large prospective studies comparing prolonged-
release tacrolimus with immediate-release tacrolimus have
been performed in de novo kidney transplantation. The first
(Study 12-03) was a randomized, double-blind, placebo-
controlled study over 24 weeks followed by an open-label
extension of 12 months [17]; the second trial, OSAKA
(Optimising immunoSuppression After Kidney trans-
plantation with Advagraf), was a 24-week, open-label, par-
allel-arm study [18]. Both studies assessed the noninferiority
of prolonged-release tacrolimus and immediate-release
tacrolimus when used in combination with mycophenolate
mofetil (MMF) and low-dose corticosteroids. The primary
endpoints differed between the 2 trials. In Study 12-03, the
primary endpoint was the incidence of biopsy-confirmed
acute rejection (BCAR) based on local diagnosis over 24
weeks of treatment [17]. The OSAKA study used a com-
posite endpoint of graft loss, BCAR, and graft dysfunction,
estimated using glomerular filtration rate (eGFR) calcu-
lated by the Modification of Diet in Renal Disease-4 for-
mula of <40 mL/min/1.73 m2 at the end-of-study visit, based
on the European Medicines Agency (EMA) guidelines[18,19]. Using a measure of graft function, as recommended
by the EMA, provides a comprehensive assessment of
treatment efficacy [20], but this endpoint has not been used
routinely in clinical trials to date. It also differs from the
advice provided by the US Food and Drug Administration
(FDA), which recommends a composite endpoint
comprising graft loss, BCAR, and loss to follow-up.
In this analysis, we used 24-week follow-up data from the
2 tacrolimus studies (12-03 and OSAKA) combined into a
single database to create a large patient population to
evaluate the effects of prolonged-release tacrolimus and
immediate-release tacrolimus formulations using different
efficacy parameters (including the EMA and FDA com-
posite endpoints). This study is the first to compare vari-
ability in exposure with prolonged-release versus
immediate-release tacrolimus in de novo kidney transplant
recipients. Early tacrolimus exposure, outcomes by donor
type, and tolerability were also evaluated for the 2 tacroli-
mus formulations.
MATERIALS AND METHODS
This analysis used data from the 12-03 (NCT00189839) and
OSAKA studies (NCT00717470), combined into a single database,
to compare outcomes with prolonged-release tacrolimus (Advagraf,
Astellas Pharma Europe BV, Leiden, the Netherlands, hereafter
termed prolonged-release tacrolimus) and immediate-release
tacrolimus (Prograf, Astellas Pharma Ltd, Chertsey, UK, here-
after termed immediate-release tacrolimus) in de novo kidney
transplantation.
Both studies enrolled adult patients with end-stage renal disease
receiving a kidney transplant from deceased or living donors with
compatible ABO blood types. Study 12-03 compared prolonged-
release tacrolimus and immediate-release tacrolimus at an initial
postoperative dose of 0.2 mg/kg per day, in combination with low-
dose MMF and corticosteroids, in a randomized, double-blind,
placebo-controlled trial [17]. OSAKA compared 4 tacrolimus-
based arms in a randomized, open-label study; only the patients
who received immediate-release tacrolimus or prolonged-release
tacrolimus at an initial dose of 0.2 mg/kg per day, in combination
with low-dose MMF and corticosteroids (arms 1 and 2), were
included in this analysis [18]. Patients in the other arms of the
OSAKA study were excluded because they received prolonged-
release tacrolimus either at a higher starting dose (0.3 mg/kg per
day) or in combination with basiliximab in a steroid-avoidance
regimen.
Both studies were conducted in accordance with the Declaration
of Helsinki, Good Clinical Practice, and the International Confer-
ence on Harmonisation guidelines [21e23]. Both studies were
approved by the Independent Ethics Committee or Institutional
Review Board at each study site. Written informed consent was
obtained from all patients before enrollment.
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In both studies, patients received a preoperative oral tacrolimus
dose of 0.1 mg/kg, administered as prolonged-release tacrolimus or
immediate-release tacrolimus. After transplantation (day 0),
tacrolimus was initiated at 0.2 mg/kg per day for both formulations;
doses were then adjusted to maintain recommended tacrolimus
whole blood trough levels: 10 to 15 ng/mL (days 1e28) and 5 to 15
ng/mL (days 29e168) for Study 12-03; and 10 to 15 ng/mL (days
1e14), 5 to 12 ng/mL (days 15e42), and 5 to 10 ng/mL (days 43e168)
for OSAKA. Immediate-release tacrolimus was taken in the
morning and evening, whereas prolonged-release tacrolimus was
taken in the morning only. Patients in Study 12-03 also received
matching placebo for prolonged-release tacrolimus or immediate-
release tacrolimus, as appropriate, to maintain study blinding.
MMF was administered preoperatively (1 g), then at 1 g
twice-daily for days 1-14, and at 500 mg twice-daily thereafter in
both studies. No induction therapy was administered. Methylpred-
nisolone (or the equivalent) was administered as an intravenous
bolus dose of up to 1000 mg (Study 12-03) or up to 500 mg
(OSAKA) perioperatively, and of 125 mg on day 1 (both studies).
Oral prednisolone (or equivalent) was started at 20 mg/d on
days 2 to 14 and tapered as follows in both studies: 15 mg/d
(days 15e28), 10 mg/d (days 29e42), 5 mg/d (days 43e84), and
0e5 mg/d (thereafter).
Assessments
In both Study 12-03 and OSAKA, BCAR (based on local pathology
following Banff 97 criteria) [24], renal function [25], graft and pa-
tient survival were evaluated at the end-of-study follow-up or last
visit [17,18]. In Study 12-03, the primary endpoint was incidence of
BCAR within 24 weeks after transplantation; renal function was
determined using creatinine clearance (CockcrofteGault) and the
eGFR was calculated using the Modification of Diet in Renal
Disease-4 formula as a post hoc analysis [17]. In OSAKA, the pri-
mary efficacy variable was the incidence of efficacy failure (based on
the EMA composite endpoint) [18], defined as incidence and time
to first occurrence of graft loss (retransplantation, nephrectomy,
death, or dialysis at study end or at time of discontinuation, unless
superseded by follow-up information that indicated graft survival),
BCAR, or graft dysfunction (defined as eGFR [Modification of
Diet in Renal Disease-4] of <40 mL/min/1.73m2) at day 168.
In this combined analysis, data collected up to the formal end-of-
study visit or the follow-up visit were used to evaluate 3 different
efficacy endpoints. These were (a) the single endpoint of BCAR, (b)
the FDA composite endpoint of graft loss, BCAR, or loss to follow-
up, and (c) the EMA composite endpoint. In addition, the mean
tacrolimus dose and mean tacrolimus whole blood levels were
assessed over the first 7 days posttransplantation and throughout
the study at predefined time points. The intrapatient variability of
tacrolimus exposure of both formulations was assessed over the
24-week study period. The incidence of delayed graft function was
defined as dialysis for >1 day within the first 7 days post-
transplantation. Tolerability profiles for both tacrolimus formula-
tions were also assessed.
Statistical Analysis
Data from the full-analysis set (FAS) for each study (all randomized
patients who had a transplant and received 1 dose of tacrolimus)
were combined into a single database. The analyses for this study
were performed using the FAS population to provide the most
conservative analysis of the data. Noninferiority was demonstratedif the lower limit of the 95% confidence interval for the difference
in efficacy failure rate was above 10% for the combined
prolonged-release tacrolimus arm versus the immediate-release
tacrolimus arm. Although this pooled analysis was retrospective, a
noninferiority margin of 10% was deemed appropriate, because this
margin was the narrower (and most difficult to meet) of the two
noninferiority margins for the two studies. In OSAKA, the pre-
defined noninferiority margin was 12.5%, whereas in Study 12-03
the margin was 10%. Tacrolimus dose and exposure were calculated
using the FAS and compared using a t test. The intrapatient vari-
ability of tacrolimus exposure was expressed as the coefficient of
variation for study completers (completer analysis). In addition,
probabilities for event-free survival for the EMA and FDA com-
posite endpoints (KaplaneMeier method) were calculated and the
homogeneity of both arms was assessed by the log-rank test. P <.05
was considered statistically significant. Laboratory parameters were
compared using an unpaired t test.RESULTS
Patient and Donor Characteristics
A total of 1278 patients, who received a starting dose of 0.2
mg/kg per day of tacrolimus, were included in the combined
analysis database (FAS). Of these, 633 patients received
prolonged-release tacrolimus (12-03, n ¼ 331; OSAKA,
n ¼ 302) and 645 received immediate-release tacrolimus
(12-03, n ¼ 336; OSAKA, n ¼ 309). In total, 1061 patients
were study completers; 508 patients (80.3%) in the
prolonged-release tacrolimus arm and 553 (85.7%) in the
immediate-release tacrolimus arm. The reasons for study
discontinuation are reported in Fig 1.
Demographics and baseline characteristics were generally
well balanced between the treatment arms (Table 1). The
majority of organs were from deceased donors (80.0%
overall) and donors <60 years old (77.7%); more than one-
half of donors were male (56.7%).
Tacrolimus Dosing and Exposure
The mean daily doses of tacrolimus were similar on day 1
but significantly higher throughout the study in the arm
receiving prolonged-release tacrolimus versus immediate-
release tacrolimus (Table 2). However, the mean  stan-
dard deviation tacrolimus trough levels were generally
significantly lower with prolonged-release tacrolimus versus
immediate-release tacrolimus throughout the study
(Table 2). The proportion of patients with tacrolimus trough
levels of 5 to 15 ng/mL was higher with prolonged-release
tacrolimus compared with immediate-release tacrolimus in
the first 2 days post-transplantation (P <.001); however, this
was comparable between arms by day 3 (Fig 2). The pro-
portion of patients with tacrolimus blood trough levels of
>20 ng/mL was significantly lower in patients treated with
prolonged-release tacrolimus compared with immediate-
release tacrolimus in the first 2 days post-transplantation
(Fig 2). In the completer analysis, prolonged-release
tacrolimus demonstrated significantly less intrapatient vari-
ability of exposure compared with immediate-release
tacrolimus by day 168 (coefficient of variation, 0.372 vs
Fig 1. Patient disposition and reasons for discontinuation in the combined analysis. aPatients in the OSAKA study were randomized to
four treatment arms. Only the prolonged-release tacrolimus and immediate-release tacrolimus arms with an initial dose of 0.2 mg/kg per
day were included in the combined analysis. All analyses in this manuscript were performed on the FAS. AE, adverse event; FAS, full-
analysis set; OSAKA, Optimising immunoSuppression After Kidney transplantation with Advagraf.
PROLONGED- AND IMMEDIATE-RELEASE TACROLIMUS 20430.398; P ¼ .015). When the data were dose-normalized by
milligram, a similar pattern was observed (0.380 vs 0.411;
P ¼ .016); however, no difference was observed when data
were dose-normalized by milligrams per day (0.384 vs 0.397;
P ¼ .286).
Concomitant Medication
As per the study design, no antibody induction therapy was
administered in either treatment arm and all patients
received low-dose MMF and corticosteroids throughout the
study. The median doses of MMF and corticosteroids at day
168 were 1 g and 5 mg, respectively, in both arms. More
than 90% of patients received maintenance steroids
throughout the study.
Efficacy Endpoints
For all 3 endpoints, the difference in response with
prolonged-release tacrolimus and immediate-release tacro-
limus ranged from 0.2% to þ2.0%, and 95% confidence
intervals were between 4.0% and þ7.4%. These data are
within the 10% margin, which demonstrates noninferiority
of prolonged-release tacrolimus versus immediate-release
tacrolimus (Table 3).The incidence of BCAR was similar with prolonged-
release tacrolimus (13.9%) and immediate-release tacroli-
mus (14.1%). The FDA composite endpoint was reached by
21.5% versus 19.8% of patients, respectively (Fig 3A); with
both treatments, BCAR was the main reason for efficacy
failure, with very few patients lost to follow-up (Table 3).
The EMA composite endpoint was reached by 40.3% of
patients treated with prolonged-release tacrolimus and
38.3% of those receiving immediate-release tacrolimus (Fig
3B); with both treatments, graft dysfunction was the domi-
nant reason for efficacy failure (Table 3). Renal function
was similar for both treatment arms at day 168 (prolonged-
release tacrolimus: 47.3 mL/min per 1.73 m2; immediate-
release tacrolimus: 49.5 mL/min per 1.73 m2).
Stratification of the patients according to deceased or
living organ donors showed no significant differences in
efficacy between the 2 treatments. For patients receiving
organs from deceased donors, the incidence of BCAR was
12.0% (61/510) for prolonged-release tacrolimus and 12.5%
(64/512) for immediate-release tacrolimus, and the inci-
dence of patients who achieved the EMA and FDA com-
posite endpoints was 40.3% (255/633) and 21.5% (136/633),
respectively, for prolonged-release tacrolimus and 38.3%
(247/645) and 19.8% (128/645) for immediate-release
Table 1. Patient and Donor Demographics and Transplantation
Information in the Combined Analysis (FAS)
Prolonged-release
Tacrolimus
(n ¼ 633)
Immediate-release
Tacrolimus
(n ¼ 645)
Recipient
Gender
Male 410 (64.8) 426 (66.0)
Female 223 (35.2) 219 (34.0)
Mean age in years (SD) 47.6 (12.8) 48.1 (12.9)
<60 510 (80.6) 528 (81.9)
60 123 (19.4) 117 (18.1)
Race
Caucasian 561 (88.6) 569 (88.2)
Black 28 (4.4) 26 (4.0)
Asian 9 (1.4) 9 (1.4)
Other 35 (5.5) 41 (6.4)
Transplant history
First transplant 605 (95.6) 612 (94.9)
Retransplant 28 (4.4) 33 (5.1)
Donor
Gender
Male 354 (55.9) 370 (57.4)
Female 279 (44.1) 275 (42.6)
Mean age in years (SD)* 48.1 (14.7) 48.0 (14.7)
<60 488 (77.1) 505 (78.3)
60 138 (21.8) 132 (20.5)
Type
Living 123 (19.4) 143 (20.6)
Deceased 510 (80.6) 512 (79.4)
HLA type mismatch, mean
A 1.0 1.0
B 1.2 1.2
DR 0.9 0.8
PRA grade
<50 624 (98.6) 640 (99.2)
50e100 6 (0.9) 3 (0.5)
Number of patients with
missing data
3 (0.5) 2 (0.3)
Mean cold ischemia
time† in minutes (SD)
960 (370) 937 (345)
Data are n (%) unless stated otherwise.
Abbreviations: FAS, full-analysis set; HLA, human leukocyte antigen; PRA,
panel-reactive antibody; SD, standard deviation.
*The number of patients excluded because of missing data was 8 in the
prolonged-release tacrolimus cohort and 7 in the immediate-release tacrolimus
cohort.
†Data are for deceased donors only.
2044 KRÄMER, ALBANO, BANAS ET ALtacrolimus. For living donor transplants, the incidence of
BCAR was 22.0% (27/123) and 18.9% (27/143) with
prolonged-release tacrolimus and immediate-release tacro-
limus, respectively. For the composite efficacy endpoints,
the incidence was 35.8% (44/123; EMA) and 25.2% (31/123;
FDA) of patients with prolonged-release tacrolimus, and
28.7% (41/143; EMA) and 21.0% (30/143; FDA) with
immediate-release tacrolimus. The incidence of delayed
graft function was similar for patients who received
prolonged-release tacrolimus versus immediate-release
tacrolimus (15.5% [98/633] vs 16.0% [103/645],
respectively).Tolerability Profile
Prolonged-release and immediate-release tacrolimus had
similar adverse event profiles over the study period. The
most common adverse events are presented in Table 4. The
incidence of new-onset diabetes mellitus (World Health
Organization/American Diabetes Association criteria) was
low throughout the study (13.4% of patients with
prolonged-release tacrolimus compared with 16.4% with
immediate-release tacrolimus; P ¼ .157). Ongoing antidia-
betic medication and ongoing insulin medication were
required by 11.9% and 6.9%, respectively, of patients
treated with prolonged-release tacrolimus, and 13.1% and
7.9%, respectively, of those treated with immediate-release
tacrolimus (P ¼ .587 and P ¼ .570, respectively). The mean
 standard deviation serum total cholesterol levels showed
slight and similar increases over the study period with
prolonged-release tacrolimus and immediate-release tacro-
limus. The mean  standard deviation triglyceride levels
decreased over the 24-week period in both arms; the low-
density lipoprotein/high-density lipoprotein cholesterol ra-
tio was similar with both treatments.
DISCUSSION
This combined analysis showed that prolonged-release
tacrolimus was noninferior to immediate-release tacroli-
mus at 24 weeks of follow-up in patients undergoing de novo
kidney transplantation, regardless of the efficacy endpoint
used. To our knowledge, this is the first study to compare
the EMA- and the FDA-recommended composite efficacy
endpoints in kidney transplantation on such a large scale. By
including graft function within the EMA composite
endpoint, these results can be considered a comprehensive
evaluation of treatment efficacy. Results from this large
population of patients demonstrated that the prolonged-
release formulation provided a narrower range of tacroli-
mus exposure versus the immediate-release formulation
over the initial 2 days after transplantation, with reduced
variability maintained over the follow-up period. This study
was the first to compare the variability in exposure for
prolonged-release versus immediate-release tacrolimus in
de novo kidney transplant recipients.
Tacrolimus is known to have a narrow therapeutic index,
with both overexposure and underexposure having poten-
tially important effects on clinical outcomes [26]. In this
study, a higher proportion of patients achieved tacrolimus
trough levels of 5 to 15 ng/mL with prolonged-release
tacrolimus versus immediate-release tacrolimus during the
first 2 days posttransplantation. A lower initial tacrolimus
exposure reported with prolonged-release tacrolimus
compared with the immediate-release formulation has also
been reported previously [15,27,28]. After the same initial
dose, adjustments to obtain target levels resulted in signifi-
cantly lower mean doses of immediate-release versus
prolonged-release tacrolimus (w 17% from days 84-168).
Significantly fewer patients receiving prolonged-release
tacrolimus experienced potentially toxic overexposure
Fig 2. The proportion of patients achieving various tacrolimus trough level ranges in the early posttransplant period (days 1e7). Only
significant P values are shown on the graph.
PROLONGED- AND IMMEDIATE-RELEASE TACROLIMUS 2045(trough levels of >20 ng/mL) in the early days after trans-
plantation compared with those receiving immediate-
release tacrolimus. It is important to note, however, that
the initial tacrolimus dose (0.2 mg/kg per day) used in the
studies included in this analysis was higher than the initial
tacrolimus dose generally used in clinical practice today.
A lower initial dose of prolonged-release tacrolimus
may result in fewer patients reaching trough levels
of >20 ng/mL.Table 2. Mean Dose and Trough Levels of Prolonged-re
Day
Prolonged-release Tacrolimus
n (n ¼ 633)
Mean tacrolimus dose (mg/kg/day)
1 630 0.148 (0.06)
2 622 0.189 (0.04)
3 613 0.183 (0.05)
4 606 0.174 (0.06)
5 605 0.170 (0.07)
6 605 0.169 (0.07)
7 599 0.173 (0.08)
84 489 0.137 (0.09)
168 506 0.116 (0.08)
Mean tacrolimus trough levels (ng/mL)
1 393 10.9 (7.5)
2 431 14.9 (8.6)
3 445 15.5 (7.9)
4 413 14.2 (6.9)
5 400 12.8 (6.5)
6 407 11.7 (5.9)
7 459 11.5 (5.7)
84 462 10.1 (3.5)
168 478 9.1 (3.5)
Data are mean (standard deviation).
*P values were calculated using a t test.Low variability of tacrolimus exposure may be important
to prevent patients’ trough levels falling outside the thera-
peutic range, because it is becoming increasingly well-
documented that high intrapatient variability in tacrolimus
exposure is associated with poorer outcomes after trans-
plantation [5e8,29e31]. In a single-center study of 297 kid-
ney transplant recipients, high intrapatient variability in
tacrolimus clearance was a significant predictor of long-term
graft failure [7]. Similarly, a study of more than 300 adultlease Tacrolimus and Immediate-release Tacrolimus
Immediate-release Tacrolimus
P*n (n ¼ 645)
643 0.147 (0.05) .872
635 0.184 (0.05) .013
630 0.171 (0.05) <.001
627 0.163 (0.06) .002
625 0.159 (0.07) .009
622 0.159 (0.07) .015
616 0.160 (0.07) .007
560 0.114 (0.07) <.001
535 0.096 (0.07) <.001
395 15.2 (8.8) <.001
458 16.8 (8.1) <.001
478 16.0 (8.3) .322
415 15.5 (7.8) .014
435 13.9 (7.1) .018
408 13.0 (6.4) .005
458 12.6 (5.6) .002
528 10.3 (3.6) .610
495 8.8 (3.2) .104
Table 3. Efficacy Failure Rates Using Alternative Endpoints
Prolonged-release Tacrolimus
(n ¼ 633)
Immediate-release Tacrolimus
(n ¼ 645)
Treatment Difference*
% (95% CI)
EMA composite endpoint 255 (40.3) 247 (38.3) 2.0 (3.4 to 7.4)
FDA composite endpoint 136 (21.5) 128 (19.8) 1.7 (2.7 to 6.1)
BCAR 88 (13.9) 91 (14.1) 0.2 (4.0 to 3.6)
Graft dysfunction† 199 (31.4) 198 (30.7) 0.7 (4.4 to 5.8)
Death‡ 12 (1.9) 10 (1.6) 0.3 (1.1 to 1.7)
Graft loss§ 51 (8.1) 36 (5.6) 2.5 (0.3 to 5.3)
Loss to follow-up 7 (1.1) 7 (1.1) 0.0 (1.1 to 1.1)
Data are n (%) unless otherwise stated.
Abbreviations: BCAR, biopsy-confirmed acute rejection; CI, confidence interval; EMA, European Medicines Agency; FDA, Food and Drug Administration.
*Difference ¼ prolonged-release tacrolimus e immediate-release tacrolimus.
†Graft dysfunction was defined as estimated glomerular filtration rate (Modification of Diet in Renal Disease-4 equation) <40 mL/min/1.73 m2.
‡Includes all deaths throughout the study and up to 6 months of follow-up.
§Graft loss was defined as retransplantation, nephrectomy, death, or dialysis at end or at time of discontinuation, unless superseded by follow-up information that
indicated graft survival.
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high variability in tacrolimus trough levels had increased 1-
year acute rejection and lower graft survival than those with
lower variability [32]. Intrapatient variability in tacrolimus
trough levels has also been found to predict graft loss and
donor-specific antibody development in patients after kid-
ney transplantation [8,31]. Interestingly, stable kidney
transplant recipients who converted from immediate-release
tacrolimus to prolonged-release tacrolimus showed signifi-
cantly lower intrapatient variability in tacrolimus trough
concentrations [11,12,16]. Data from our analysis demon-
strated that intrapatient variability was significantly lower in
the patients receiving prolonged-release tacrolimus versus
immediate-release tacrolimus over 168 days post-
transplantation. However, no difference was observed when
the data were dose normalized by milligrams per day. It is
also important to note that the difference in variabilityFig 3. KaplaneMeier estimates of time to efficacy failure for the (A) FD
posite endpoint, graft dysfunction was defined as the estimated glom
tion) of <40 mL/min/1.73 m2 (from the first day of reaching graft dysfu
graft loss, BCAR, and graft dysfunction. The FDA composite endp
confirmed acute rejection; EMA, European Medicines Agency; FDA,between the 2 tacrolimus formulations was only observed
for the completer analysis and that variability in tacrolimus
exposure in the early posttransplant period remains
difficult to measure accurately owing to changes in tacroli-
mus dose.
Prolonged-release tacrolimus was noninferior to
immediate-release tacrolimus for all 3 measures of efficacy
used in this analysis, though the level of efficacy reported
varied with the definition. In our analysis, efficacy failure
rate was highest for the EMA versus FDA composite
endpoint (the proportion of patients reaching the EMA
composite endpoint was approximately double that of the
FDA endpoint at day 168). Graft dysfunction was the main
driver of failure for the EMA composite endpoint; however,
the proportion of patients experiencing graft dysfunction
was comparable between treatments (31.4% prolonged-
release tacrolimus; 30.7% immediate-release tacrolimus),A and (B) EMA composite efficacy endpoints. For the EMA com-
erular filtration rate (Modification of Diet in Renal Disease-4 equa-
nction until the end of the study). The EMA composite endpoint is
oint is graft loss, BCAR, and loss to follow-up. BCAR, biopsy-
Food and Drug Administration.
Table 4. Most Common Adverse Events and Laboratory Parameters
Prolonged-release Tacrolimus (n ¼ 633) Immediate-release Tacrolimus (n ¼ 645) P value*
Most common adverse events
Anemia 202 (31.9) 185 (28.7)
Urinary tract infection 158 (25.0) 169 (26.2)
Diarrhea 151 (23.9) 160 (24.8)
Hyperglycemia 101 (16.0) 99 (15.3)
Constipation 90 (14.2) 98 (15.2)
New-onset diabetes mellitus† 74 (13.4) 95 (16.4)
Hyperkalemia 84 (13.3) 100 (15.5)
Peripheral edema 89 (14.1) 93 (14.4)
Tremor 93 (14.7) 89 (13.8)
Laboratory parameters
Serum total cholesterol levels (mg/dL)
Baseline 187.0  49.9 182.7  47.3 .174
Day 168 197.3  45.3 193.9  44.3 .276
Triglyceride levels (mg/dL)
Baseline 193.6  145.3 190.2  130.0 .635
Day 168 178.8  126.8 167.4  94.1 .111
LDL/HDL cholesterol ratio
Baseline 2.4  1.0 2.3  1.1 .138
Day 168 2.5  1.0 2.5  1.9 .831
Data are n (%) or mean  standard deviation.
Abbreviation: LDL/HDL, low-density/high-density lipoprotein cholesterol.
*P values were calculated using an unpaired t test.
†Excludes patients with diabetes at baseline.
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lations. In a previous study in de novo kidney transplant
patients, renal function parameters were also similar with
prolonged-release tacrolimus versus immediate-release
tacrolimus over 12 months of follow-up [33]. In a single-
center observational study by Tinti et al [27], a significant
improvement in eGFR over 6 months was reported after
conversion from immediate-release tacrolimus to
prolonged-release tacrolimus, whereas van Hooff et al [34]
and Guirado et al [28] demonstrated stable renal function
for up to 4 years in kidney transplant patients who had
received de novo prolonged-release tacrolimus, and also in
those who had been converted from the immediate-release
to the prolonged-release formulation.
A previous randomized, controlled study in de novo
kidney transplant recipients used the FDA composite
endpoint and showed a similar efficacy failure rate with
prolonged-release tacrolimus and immediate-release tacro-
limus (14.0% vs 15.1%, respectively) at 1 year post-
transplantation [33]. The lower rates compared with the
current analysis probably reflect differences in the organ-
donor population; approximately 50% of organs were from
deceased donors compared with 80% in the current analysis.
However, perhaps the most important factor was the use of
antibody induction by Silva et al [33] versus no antibody
induction in the current analysis.
Comparable tolerability profiles were observed with
prolonged-release tacrolimus and immediate-releasetacrolimus, consistent with findings from previous studies in
kidney and liver transplant settings [33,35e37]. The inci-
dence of new-onset diabetes mellitus was slightly, but not
significantly, lower with prolonged-release versus
immediate-release tacrolimus, with correspondingly lower
antidiabetic medication and insulin use in the prolonged-
release tacrolimus arm, although again this difference was
not significant.
The characteristics of the populations involved in the 2
studies were largely similar, hence their suitability for
combining into a single database. There were only minor
differences in treatment regimens between the 0.2 mg/kg
per day arms in Study 12-03 and OSAKA. Although the
target whole blood trough ranges were narrower in OSAKA
than Study 12-03, the same target trough range over the first
14 days post-transplantation (10e15 ng/mL) allowed early
exposure to be compared between the 2 formulations in this
combined analysis. However, there are limitations to this
study, including those reported for the individual studies
[17,18]. In Study 12-03, both treatment arms showed equally
well-maintained renal function at 12 months; however, only
24-week data have been published for the OSAKA study.
More patients in the immediate-release tacrolimus arm of
the OSAKA study experienced BCAR than did those in the
prolonged-release tacrolimus arm, whereas it was the
opposite in Study 12-03. It is possible that these differences
could be due to the optimization of the overall immuno-
suppressive regimen with prolonged-release tacrolimus over
2048 KRÄMER, ALBANO, BANAS ET ALthe time between the two studies, because Study 12-03 was
concluded a year and a half before enrollment into the
OSAKA study.
CONCLUSIONS
This analysis from a combined database of two large, ran-
domized trials enabled comparison of the treatments using
three different efficacy measures (BCAR, and EMA and
FDA composite endpoints) in kidney transplantation.
Regardless of the measure used, prolonged-release tacroli-
mus was noninferior to immediate-release tacrolimus
treatment in de novo kidney transplantation. The propor-
tion of patients who achieved trough levels of 5 to 15 ng/mL
was higher with prolonged-release tacrolimus compared
with immediate-release tacrolimus early after trans-
plantation, and tolerability profiles were comparable
between the 2 formulations.
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